The protease-antiprotease battle in the cystic fibrosis lung.
作者信息
Balfour-Lynn I M
机构信息
Department of Paediatric Respiratory Medicine, Royal Brompton & Harefield NHS Trust, London, UK.
出版信息
J R Soc Med. 1999;92 Suppl 37(Suppl 37):23-30. doi: 10.1177/014107689909237S05.
Abstract
摘要
相似文献
1
The protease-antiprotease battle in the cystic fibrosis lung.
J R Soc Med. 1999;92 Suppl 37(Suppl 37):23-30. doi: 10.1177/014107689909237S05.
2
Reduction in neutrophil elastase concentration by recombinant alphal-antitrypsin (recAAT) does not alter bacterial loading in the sputum of cystic fibrosis patients.
Br J Biomed Sci. 2004;61(3):146-7. doi: 10.1080/09674845.2004.11732661.
3
Secretory leukocyte protease inhibitor in cystic fibrosis.
Agents Actions Suppl. 1993;42:103-10. doi: 10.1007/978-3-0348-7397-0_9.
4
Neutrophil proteinases and rhDNase therapy in cystic fibrosis.
Eur Respir J. 1996 Nov;9(11):2193-5. doi: 10.1183/09031936.96.09112193.
5
Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency.
Ann Am Thorac Soc. 2016 Apr;13 Suppl 2:S191-6. doi: 10.1513/AnnalsATS.201504-245KV.
6
Protease-antiprotease imbalance in the lungs of children with cystic fibrosis.
Am J Respir Crit Care Med. 1994 Jul;150(1):207-13. doi: 10.1164/ajrccm.150.1.7912987.
7
Inhibition of airway proteases in cystic fibrosis lung disease.
Eur Respir J. 2008 Sep;32(3):783-95. doi: 10.1183/09031936.00146807.
8
Revisiting alpha1-antitrypsin therapy in cystic fibrosis: can it still offer promise?
Eur Respir J. 2007 Feb;29(2):229-30. doi: 10.1183/09031936.00159606.
9
Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation.
Pediatr Res. 1996 Jul;40(1):130-4. doi: 10.1203/00006450-199607000-00022.
10
Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential.
Am J Respir Crit Care Med. 2020 Jan 15;201(2):141-147. doi: 10.1164/rccm.201906-1190PP.
引用本文的文献
1
Towards better understanding of the heparin role in NETosis: feasibility of using native mass spectrometry to monitor interactions of neutrophil elastase with heparin oligomers.
Int J Mass Spectrom. 2021 May;463. doi: 10.1016/j.ijms.2021.116550. Epub 2021 Feb 14.
2
Interactions between Neutrophils and Pseudomonas aeruginosa in Cystic Fibrosis.
Pathogens. 2017 Mar 9;6(1):10. doi: 10.3390/pathogens6010010.
3
Quantitative proteomics reveals an altered cystic fibrosis in vitro bronchial epithelial secretome.
Am J Respir Cell Mol Biol. 2015 Jul;53(1):22-32. doi: 10.1165/rcmb.2014-0256RC.
4
Sirtinol inhibits neutrophil elastase activity and attenuates lipopolysaccharide-mediated acute lung injury in mice.
Sci Rep. 2015 Feb 10;5:8347. doi: 10.1038/srep08347.
5
Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products.
Antimicrob Agents Chemother. 2014 Nov;58(11):6851-60. doi: 10.1128/AAC.03514-14. Epub 2014 Sep 2.
6
Transgenic α-1-antitrypsin secreted into the bloodstream from salivary glands is biologically active.
Oral Dis. 2011 Jul;17(5):476-83. doi: 10.1111/j.1601-0825.2010.01775.x. Epub 2010 Dec 2.
7
Antiproteases as therapeutics to target inflammation in cystic fibrosis.
Open Respir Med J. 2010 Mar 30;4:20-31. doi: 10.2174/1874306401004020020.
8
Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy.
J Med Microbiol. 2009 Apr;58(Pt 4):492-502. doi: 10.1099/jmm.0.005728-0.
9
Highlights of a workshop to discuss targeting inflammation in cystic fibrosis.
J Cyst Fibros. 2009 Jan;8(1):1-8. doi: 10.1016/j.jcf.2008.10.002. Epub 2008 Nov 20.
10
X-ray snapshot of the mechanism of inactivation of human neutrophil elastase by 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives.
J Med Chem. 2008 Apr 10;51(7):2003-8. doi: 10.1021/jm700966p. Epub 2008 Mar 5.
本文引用的文献
1
High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.
Eur Respir J. 1998 Aug;12(2):271-6. doi: 10.1183/09031936.98.12020271.
2
Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option?
Thorax. 1998 Feb;53(2):114-6. doi: 10.1136/thx.53.2.114.
3
Alpha1-antitrypsin deficiency alleles and the Taq-I G-->A allele in cystic fibrosis lung disease.
Eur Respir J. 1998 Apr;11(4):873-9. doi: 10.1183/09031936.98.11040873.
4
Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells.
J Clin Invest. 1998 Jun 1;101(11):2598-605. doi: 10.1172/JCI2865.
5
Positive correlation of algD transcription to lasB and lasA transcription by populations of Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis.
Infect Immun. 1997 Oct;65(10):4061-7. doi: 10.1128/iai.65.10.4061-4067.1997.
6
Current understanding of the inflammatory process in cystic fibrosis: onset and etiology.
Pediatr Pulmonol. 1997 Aug;24(2):137-42; discussion 159-61. doi: 10.1002/(sici)1099-0496(199708)24:2<137::aid-ppul13>3.0.co;2-3.
7
The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers.
Am J Respir Crit Care Med. 1997 Feb;155(2):536-41. doi: 10.1164/ajrccm.155.2.9032191.
8
Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation.
Thorax. 1996 Dec;51(12):1273-4. doi: 10.1136/thx.51.12.1273.
9
Neutrophil proteinases and rhDNase therapy in cystic fibrosis.
Eur Respir J. 1996 Nov;9(11):2193-5. doi: 10.1183/09031936.96.09112193.
10
Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride.
J Immunol. 1996 Sep 15;157(6):2728-35.
Zotero 插件